Abstract 308P
Background
It is hard to prevent 5-fluorouracil (5-FU) related oral mucositis (OM). The aim of this study was to determine the association between dental prophylactic modalities and the risk of OM in HNC patients with 5-FU-related treatment.
Methods
During 2000 to 2008, 20,715 HNC (ICD-9-CM 140-149) patients with newly 5-FU-related chemotherapy were selected from the registry of LHID-CIP, and the date of 5-FU therapy initiation was defined as the index date. These HNC patients were stratified into three groups according to their cancer locations: oral cancers (ICD-9-CM 140-145), nasopharyngeal cancer (NPC, ICD-9-CM 147) and other cancers (ICD-9-CM 146, 148 and 149).The end date was defined as the date of OM diagnosis, withdrawal from the NHI program, or the 21thday after the day of 5-FU therapy initiation, whichever came first. Patients with OM diagnosis (ICD-9 CM 528.00, 528.01, 528.2, and 528.9). The records of dental treatment was determined for each patient within 180 days prior to the index date, which included fluoride gel application, chlorhexidine mouth rinse, scaling, and major oral surgery. Based on the different dental prophylactic modalities, all HNC subjects were stratified into different groups. Odds ratios (OR) and 95% confidence intervals (CI) were determined by multiple logistic regression model.
Results
13,969 HNC participants, including 482 5-FU-related OM subjects and 13,487 controls were enrolled. Fluoride gel application and scaling were significantly related to OM development (p < 0.001). 2.25-fold increased risk of OM while scaling was performed within three weeks before 5-FU-related chemotherapy (95% CI = 1.81–2.81), and a 3.22-fold increased risk of OM while fluoride gel was applied during 5-FU-related treatment (95% CI = 1.46–7.13).
Conclusions
This study highlighted a remarkable association between dental prophylactic modalitiesand the risk of 5-FU-related OM in HNC population.Clinical practitioners have to be vigilant about the joint effect of scaling and fluoride gel application in the increased risk of OM. Optimal timing of scaling and appropriate fluoride gel application strategy are necessary in reducing the risk of 5-FU-related OM.
Clinical trial identification
Editorial acknowledgement
This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003), Chang Gung Memorial Hospital (CMRPG3I0151), Far Eastern Memorial Hospital (FEMH-2019-C-039), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract